BioHarvest Sciences Inc. Common Stock (BHST) - Net Assets
Based on the latest financial reports, BioHarvest Sciences Inc. Common Stock (BHST) has net assets worth $19.76 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($44.57 Million) and total liabilities ($24.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See BioHarvest Sciences Inc. Common Stock (BHST) balance sheet quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $19.76 Million |
| % of Total Assets | 44.34% |
| Annual Growth Rate | 69.38% |
| 5-Year Change | 791.35% |
| 10-Year Change | N/A |
| Growth Volatility | 886.38 |
BioHarvest Sciences Inc. Common Stock - Net Assets Trend (2013–2025)
This chart illustrates how BioHarvest Sciences Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see BHST market cap.
Annual Net Assets for BioHarvest Sciences Inc. Common Stock (2013–2025)
The table below shows the annual net assets of BioHarvest Sciences Inc. Common Stock from 2013 to 2025. Also explore BioHarvest Sciences Inc. Common Stock net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $25.45 Million | +1813.38% |
| 2024-12-31 | $1.33 Million | +108.95% |
| 2023-12-31 | $-14.85 Million | -150.51% |
| 2022-12-31 | $-5.93 Million | -307.67% |
| 2021-12-31 | $2.85 Million | +224.40% |
| 2020-12-31 | $-2.29 Million | +91.49% |
| 2019-12-31 | $-26.97 Million | -1075.74% |
| 2018-12-31 | $2.76 Million | +908.60% |
| 2017-12-31 | $274.05K | +560.05% |
| 2016-12-31 | $-59.57K | -470.34% |
| 2015-12-31 | $16.09K | -7.21% |
| 2014-12-31 | $17.34K | -62.01% |
| 2013-12-31 | $45.63K | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioHarvest Sciences Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10748741300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $133.00 Million | 522.64% |
| Total Equity | $25.45 Million | 100.00% |
BioHarvest Sciences Inc. Common Stock Competitors by Market Cap
The table below lists competitors of BioHarvest Sciences Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Comtrend Corp
TWO:8089
|
$37.64 Million |
|
InCity Immobilien AG
XETRA:IC8
|
$37.65 Million |
|
aTyr Pharma, Inc.
NASDAQ:ATYR
|
$37.66 Million |
|
Shagrir Group Vehicle Services Ltd
TA:SHGR
|
$37.66 Million |
|
FRIWO AG
F:CEA
|
$37.60 Million |
|
DocGo Inc
NASDAQ:DCGO
|
$37.60 Million |
|
Yellow Balloon Tour Co. Ltd
KQ:104620
|
$37.59 Million |
|
Cellumed Co. Ltd
KQ:049180
|
$37.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioHarvest Sciences Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,330,000 to 25,448,000, a change of 24,118,000 (1813.4%).
- Net loss of 11,135,000 reduced equity.
- New share issuances of 18,262,000 increased equity.
- Other factors increased equity by 16,991,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.13 Million | -43.76% |
| Share Issuances | $18.26 Million | +71.76% |
| Other Changes | $16.99 Million | +66.77% |
| Total Change | $- | 1813.38% |
Book Value vs Market Value Analysis
This analysis compares BioHarvest Sciences Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.20x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.08x to 1.20x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.80 | $1.66 | x |
| 2014-12-31 | $0.06 | $1.66 | x |
| 2015-12-31 | $0.10 | $1.66 | x |
| 2016-12-31 | $-0.14 | $1.66 | x |
| 2017-12-31 | $0.47 | $1.66 | x |
| 2018-12-31 | $1.69 | $1.66 | x |
| 2019-12-31 | $-10.35 | $1.66 | x |
| 2020-12-31 | $-0.24 | $1.66 | x |
| 2021-12-31 | $0.23 | $1.66 | x |
| 2022-12-31 | $-0.45 | $1.66 | x |
| 2023-12-31 | $-1.10 | $1.66 | x |
| 2024-12-31 | $0.08 | $1.66 | x |
| 2025-12-31 | $1.38 | $1.66 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioHarvest Sciences Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -43.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -32.27%
- • Asset Turnover: 0.72x
- • Equity Multiplier: 1.87x
- Recent ROE (-43.76%) is above the historical average (-168.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -319.59% | 0.00% | 0.00x | 1.88x | $-127.60K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-97.46K |
| 2017 | -1.82% | 0.00% | 0.00x | 1.10x | $-32.40K |
| 2019 | 0.00% | -2435.78% | 0.11x | 0.00x | $-2.26 Million |
| 2020 | 0.00% | -1662.63% | 0.07x | 0.00x | $-6.35 Million |
| 2021 | -344.20% | -467.51% | 0.21x | 3.58x | $-10.11 Million |
| 2022 | 0.00% | -204.37% | 0.59x | 0.00x | $-10.64 Million |
| 2023 | 0.00% | -99.15% | 0.84x | 0.00x | $-11.08 Million |
| 2024 | -970.90% | -51.27% | 1.01x | 18.80x | $-13.05 Million |
| 2025 | -43.76% | -32.27% | 0.72x | 1.87x | $-13.68 Million |
Industry Comparison
This section compares BioHarvest Sciences Inc. Common Stock's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $83,473,726
- Average return on equity (ROE) among peers: -45.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioHarvest Sciences Inc. Common Stock (BHST) | $19.76 Million | -319.59% | 1.26x | $37.63 Million |
| Above Food Ingredients Inc. Common Stock (ABVE) | $29.11 Million | -156.27% | 0.05x | $4.86 Million |
| Agape ATP Corporation Common Stock (ATPC) | $2.30 Million | -3.27% | 0.00x | $2.34 Million |
| B&G Foods Inc (BGS) | $524.81 Million | -47.87% | 4.71x | $252.49 Million |
| BranchOut Food Inc. Common Stock (BOF) | $2.34 Million | -202.92% | 4.49x | $60.32 Million |
| Bellring Brands LLC (BRBR) | $-376.20 Million | 0.00% | 0.00x | $1.06 Billion |
| BRC Inc. (BRCC) | $-149.49 Million | 0.00% | 0.00x | $216.27 Million |
| BRF SA ADR (BRFS) | $675.64 Million | 1.22% | 3.45x | $5.38 Billion |
| Bridgford Foods Corporation (BRID) | $28.20 Million | 19.86% | 0.40x | $53.01 Million |
| Borealis Foods Inc. (BRLS) | $14.56 Million | -20.21% | 0.51x | $28.76 Million |
About BioHarvest Sciences Inc. Common Stock
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science-based health and w… Read more